3.29
price down icon17.13%   -0.68
after-market Dopo l'orario di chiusura: 3.26 -0.03 -0.91%
loading
Precedente Chiudi:
$3.97
Aprire:
$3.795
Volume 24 ore:
43.30M
Relative Volume:
2.75
Capitalizzazione di mercato:
$1.10B
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.9701
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
+40.60%
1M Prestazione:
+75.00%
6M Prestazione:
-47.36%
1 anno Prestazione:
-63.96%
Intervallo 1D:
Value
$3.28
$4.04
Intervallo di 1 settimana:
Value
$2.22
$4.13
Portata 52W:
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Nome
Iovance Biotherapeutics Inc
Name
Telefono
(650) 260-7120
Name
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Dipendente
838
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
IOVA's Discussions on Twitter

Confronta IOVA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
3.29 1.33B 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-15 Downgrade Goldman Neutral → Sell
2025-05-16 Downgrade UBS Buy → Neutral
2025-05-12 Downgrade Truist Buy → Hold
2025-05-09 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 Iniziato UBS Buy
2024-07-29 Downgrade Piper Sandler Overweight → Neutral
2023-11-20 Iniziato Goldman Buy
2023-09-18 Reiterato Barclays Overweight
2023-05-30 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-27 Aggiornamento Piper Sandler Neutral → Overweight
2022-12-09 Downgrade Goldman Buy → Neutral
2022-10-31 Iniziato Guggenheim Neutral
2022-08-18 Ripresa Wells Fargo Equal Weight
2022-01-28 Aggiornamento Stifel Hold → Buy
2021-12-07 Ripresa Cowen Outperform
2021-06-10 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 Downgrade Piper Sandler Overweight → Neutral
2021-05-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 Downgrade Stifel Buy → Hold
2021-05-03 Iniziato Truist Buy
2021-04-16 Iniziato Goldman Buy
2021-03-08 Aggiornamento H.C. Wainwright Neutral → Buy
2020-12-15 Downgrade H.C. Wainwright Buy → Neutral
2020-10-06 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-22 Iniziato Mizuho Buy
2020-03-04 Iniziato Barclays Overweight
2020-02-26 Reiterato H.C. Wainwright Buy
2020-02-26 Reiterato Oppenheimer Outperform
2019-12-18 Iniziato JMP Securities Mkt Outperform
2019-10-01 Iniziato Stifel Buy
2019-04-29 Iniziato Piper Jaffray Overweight
2019-02-28 Reiterato Chardan Capital Markets Buy
2019-02-07 Iniziato Robert W. Baird Outperform
2018-12-31 Ripresa B. Riley FBR Buy
2018-07-06 Reiterato Chardan Capital Markets Buy
2018-04-10 Aggiornamento B. Riley FBR, Inc. Neutral → Buy
2018-03-13 Reiterato B. Riley FBR, Inc. Neutral
2018-02-23 Downgrade B. Riley FBR, Inc. Buy → Neutral
2018-01-25 Reiterato H.C. Wainwright Buy
2017-11-01 Reiterato B. Riley FBR, Inc. Buy
Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

pulisher
Jul 24, 2025

Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com

Jul 24, 2025
pulisher
Jul 24, 2025

Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative

Jul 23, 2025
pulisher
Jul 23, 2025

Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade

Jul 23, 2025
pulisher
Jul 23, 2025

Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com

Jul 23, 2025
pulisher
Jul 23, 2025

Where are the Opportunities in (IOVA) - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Jul 22, 2025
pulisher
Jul 21, 2025

Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - The Motley Fool

Jul 21, 2025
pulisher
Jul 20, 2025

Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World

Jul 18, 2025
pulisher
Jul 17, 2025

Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade

Jul 17, 2025
pulisher
Jul 16, 2025

Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener

Jul 14, 2025

Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):